Kandepres

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kandepres

Property Description
Active ingredient Candesartan cilexetil (Prodrug)
Form Tablet (Oral administration)
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Origin Synthetic compound
Single/Combination Single-component product (Monotherapy)

Kandepres is a prescription-only medication classified as a cardiovascular agent, designed to support the circulatory system by modulating blood flow and pressure. This synthetic compound has a defined pharmacological profile, forming a component of therapeutic strategies focused on adults requiring circulatory support.

What Type of Cardiovascular Agent is Kandepres?

Kandepres belongs to the pharmacological class of Angiotensin II Receptor Blockers (ARBs), positioning it as a Sartan drug within this category. This classification signifies a mechanism that specifically blocks the effects of a key vasoconstricting hormone. This targeted action contributes to effective regulation and sustained blood pressure reduction.

Composition and Form: The Role of Candesartan Cilexetil

The active ingredient in Kandepres is Candesartan cilexetil, which is formulated as an inactive chemical entity known as a prodrug. This prodrug status is a factor in its composition, designed to enhance the substance's stability and absorption profile. Following its necessary oral administration, this prodrug is converted by the body into the therapeutically active substance, Candesartan. This process determines its composition and systemic availability.

What is the General Therapeutic Purpose of Kandepres?

The general therapeutic purpose of Kandepres is to reduce resistance in the circulatory system by causing controlled vasodilation, thus mitigating strain on the arteries. This physiological action is a consequence of the drug's intended interference with the Renin-Angiotensin-Aldosterone System (RAAS). By promoting vessel widening, Kandepres fulfills its primary role in maintaining beneficial circulatory dynamics, assisting in the management of elevated arterial pressure.

Regulatory References

  1. Candesartan - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Kandepres?

Possible side effects and safety information

Official safety documentation classifies the possible side effects of Kandepres (candesartan cilexetil) based on frequency and the body's systems affected, according to regulatory standards.

Adverse reactions are formally grouped into System-Organ Classes, including effects on the Nervous System (e.g., dizziness, headache), Vascular Disorders (e.g., hypotension), Renal and Urinary Disorders (e.g., renal impairment), and the Metabolism and Nutrition Disorders (e.g., hyperkalemia).


Adverse Reaction Frequencies

Classification Examples of Documented Reactions
Common Headache, Dizziness, Respiratory Tract Infection, Hypotension, Hyperkalemia
Uncommon Nausea, Angioedema, Rash, Urticaria
Rare/Very Rare Neutropenia, Renal Failure, Hyponatremia

Serious Safety Characteristics

Certain adverse reactions, while rare, are defined as clinically significant in official labeling. These include Angioedema (swelling of the face, lips, or throat) and the potential for severe Renal Failure. Hematological events, such as Neutropenia, are also documented as rare serious effects.

Safety notes specify that certain reactions, such as Hypotension and Hyperkalemia, require particular observation at the initiation of therapy and when adjusting the dose. Furthermore, specific population constraints are noted: the drug is Contraindicated in individuals with Severe Hepatic Impairment and during the second and third trimesters of pregnancy. Patients being treated for Chronic Heart Failure have a documented higher reported incidence of reactions like hypotension and renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Kandepres (candesartan cilexetil) is primarily characterized by the physiological effects of excessive blood pressure lowering. The most common officially documented manifestation is symptomatic hypotension (low blood pressure), which may lead to clinical signs such as profound dizziness or fainting. Fast or slow heart rates may also be observed in such situations.

Seeking Emergency Medical Care

In any suspected overdose situation, it is required to seek immediate medical attention. Urgent medical help, such as calling emergency services, is mandated if the individual has severe symptoms, including collapse, seizures, or trouble breathing. Authorities also advise contacting a poison control helpline in case of overdose.

Officially Documented Management

The official prescribing information indicates that no specific antidote is known for candesartan overdose. Management is strictly symptomatic and supportive. For cases involving symptomatic hypotension, the described procedures include placing the patient in a supine position with the legs elevated and instituting volume expansion through intravenous fluid infusion. If these measures are insufficient, the use of sympathomimetic medicinal products may be considered. It is also documented that the active component, candesartan, is not removed by haemodialysis.

Therapeutic Uses of Kandepres

What Kandepres Treats: Main Uses and Benefits

The primary role of Kandepres is to provide support for chronic conditions involving symptoms related to systemic imbalance in the cardiovascular system. The medication is generally used to help manage three core therapeutic domains, which include elevated arterial pressure (hypertension), symptomatic chronic heart failure, and the need for supportive management for kidney function in specific high-risk patients. Such applications are representative of its use within the context of long-term cardiovascular care.

Key Therapeutic Support

The medicine may assist with addressing symptom clusters that create noticeable physiological strain. It is generally applied in scenarios where situations requiring continuous supportive management is appropriate, such as managing the ongoing burden of hypertension in adults and children, or providing support for symptomatic chronic heart failure in adults.

“This therapy supports functional stability, which contributes to easing the overall symptom load and may assist with maintaining day-to-day comfort.”

By assisting with blood pressure reduction, the medication contributes to easing the overall systemic strain and may assist with reducing the symptomatic burden associated with cardiovascular risk. For heart failure patients, it helps manage symptoms like fluid retention (edema) and exertional fatigue, contributing to more stable functioning within the circulatory system.

Quick Fact: Relief for Fluid Retention This medicine helps manage the symptoms related to fluid-related systemic imbalance that often manifest as swelling, supports general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Kandepres?

The population eligibility for Kandepres (candesartan cilexetil) is strictly defined by official regulatory bodies, focusing on contraindications and specific group limitations.

Absolute Contraindications

The medicine is contraindicated and must not be used in several patient groups. This includes women in the second and third trimesters of pregnancy due to risk of fetal toxicity, and children aged below one year for the treatment of hypertension. Individuals with severe hepatic impairment or cholestasis are also prohibited from using Kandepres. Additionally, use is forbidden in patients with diabetes mellitus or renal impairment (GFR less than 60 mL/min/1.73m^2) who are concurrently taking aliskiren.

Approved and Restricted Populations

Kandepres is approved for use in adults for both hypertension and symptomatic heart failure. For pediatric hypertension, it is approved in children from one to 17 years of age (FDA criteria). Use is not recommended in patients with primary hyperaldosteronism or in women who are breastfeeding.

Age/Condition Regulatory Status
Pregnancy (2nd/3rd Trimester) Contraindicated
Severe Hepatic Impairment Contraindicated
Children < 1 Year Contraindicated
Moderate Hepatic Impairment Use with Caution
Volume/Salt Depletion Use with Restriction

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Kandepres (Candesartan cilexetil) focuses on pharmacodynamic reinforcement and specific combination restrictions.

Interaction Classifications

Co-administration with Aliskiren is formally contraindicated in patients diagnosed with Type 2 diabetes mellitus or those with moderate-to-severe renal impairment (estimated GFR < 60 mL/min/1.73 m²).

Documented Pharmacodynamic Interactions

Interacting Agents Officially Documented Outcome
Potassium-sparing diuretics and Potassium supplements Additive risk of hyperkalemia (elevated potassium levels).
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Reduced antihypertensive effect and additive risk of renal function deterioration. This risk is noted as heightened in elderly or volume-depleted patients.
Lithium-containing products Increased serum Lithium concentrations due to reduced renal clearance of Lithium.
Other antihypertensive agents May result in an additive antihypertensive effect (hypotension).

Pharmacokinetic Neutrality

Official labeling confirms that the bioavailability of the active ingredient is not significantly affected by food, meaning Kandepres can be administered with or without meals. Furthermore, Candesartan is not a documented substrate, inhibitor, or inducer of major metabolic enzymes (CYP450), indicating that significant metabolic-based interactions are not expected.

Mechanism of Action

Blocking the Angiotensin II Receptor ( AT1)

Kandepres is a selective antagonist that works by binding to the Angiotensin II Type 1 ( AT1) receptors on cell surfaces. This action blocks the effect of the hormone Angiotensin II, preventing it from initiating the signals that contribute to Angiotensin II-mediated signaling within the Renin-Angiotensin-Aldosterone System (RAAS).


Modulating Vascular Tone and Resistance

By blocking the AT1 receptor, the drug suppresses Angiotensin II-mediated signals that cause vascular smooth muscle contraction. This mechanism promotes the relaxation and widening of the blood vessels (vasodilation), which decreases systemic vascular resistance (SVR).


Influencing Fluid and Electrolyte Balance

The drug's mechanism also indirectly affects the release of the hormone aldosterone, resulting in decreased levels. This hormonal change supports a greater excretion of sodium and water by the kidneys, influencing fluid balance which contributes to a reduction in plasma volume.

Dosage and Administration Information

Kandepres (candesartan cilexetil) is administered orally and is typically taken once daily. The medication may be taken with or without food.

Official Dosing and Titration Schedule

The dosage must be individualized by a healthcare professional. For adults, the recommended initial dose for heart failure is 4 mg once daily, and the target maintenance dose is 32 mg once daily. This target dose is achieved by doubling the dose at approximately two-week intervals, as tolerated by the patient. For adult hypertension, the usual recommended starting dose is 16 mg once daily for patients who are not volume-depleted; the total daily dose ranges from 8 mg to 32 mg.

Special Administration Conditions

  • Missed Dose: If a dose is missed, patients should not take two doses to make up for the missed one. The regular dosing schedule should be continued with the next dose.
  • Dose Adjustment: Consideration must be given to initiating Kandepres at a lower dose (e.g., 2 mg or 8 mg) for patients with volume depletion or moderate hepatic (liver) impairment.
  • Pediatric Use: For patients aged 1 to less than 17 years, specific dosing is based on age and body weight, and may require the use of an oral suspension. Instructions for preparing this oral suspension are provided for compounding by a pharmacist.

Recent Clinical Evidence

Evidence for Use in Elevated Arterial Pressure (Hypertension)

Research for this use was evaluated in Randomized Controlled Trials (RCTs) across adults and specific pediatric populations. These studies were used in research exploring how symptoms change by monitoring systolic and diastolic blood pressure readings. Longer-term surveillance was also observed in studies to monitor the occurrence of major cardiovascular events over several years in adults. Studies reported measurements of changes in blood pressure and described patterns of sustained observations. However, research exploring long-term outcomes in the youngest pediatric population (ages 1 to <6 years) is not well characterized, and data for certain groups remain insufficient regarding the full dose-response relationship.


Evidence for Use in Symptomatic Chronic Heart Failure

This clinical situation was evaluated in large-scale, multi-year, placebo-controlled clinical programs. The research examined outcomes describing episodic or acute changes, specifically focusing on the time until a defined event, such as cardiovascular death or hospitalization for heart failure. Findings described patterns observed in the studies related to the rates of these events compared to a placebo group. Studies monitored adults with reduced heart function, but patients with severe renal impairment were generally excluded from the major outcome trials, meaning comparative evidence for this specific comorbidity group is lacking.


Evidence for Supportive Management for Kidney Function

The research for this indication was observed in RCTs focusing on cohorts with coexisting Type 2 Diabetes and hypertension. The studies tracked patterns of change in important biomarkers, primarily the amount of protein (albumin) excreted in the urine. Data show patterns related to the time to progression of functional decline across the studied cohorts when compared to placebo. Specific subgroups, such as those with non-diabetic causes of kidney disease, are not fully established by existing research.


Research Context and Uncertainties

Research has explored follow-up durations reaching up to four years in major clinical programs for chronic heart failure. However, the research exploring long-term outcomes is generally not fully established for all populations, particularly concerning the durability of observations in the youngest age groups. Data for certain groups, such as children with severe kidney impairment, remain insufficient. Comparative evidence is lacking for many alternative dosing regimens, and research does not determine whether an individual will respond similarly across all monitored outcomes.

Frequently Asked Questions (FAQ)

Common questions about Kandepres (FAQ)

Q: Is Kandepres a long-term medication that people take for many years?

According to official product information, Kandepres is generally described as safe for long-term use. For chronic conditions like high blood pressure, studies indicate that the medication is intended for extended duration to support the maintenance of blood pressure goals.

Q: How long does it typically take to feel the full effect of Kandepres on blood pressure?

Official regulatory documents indicate that most of the blood pressure reduction is often present within the first two weeks. However, the maximal or full therapeutic effect is generally achieved after four to six weeks of treatment.

Q: Can Kandepres lead to muscle cramps or weakness?

Official documentation lists muscle pain, known as myalgia, as a documented possible effect of the medication. Other related effects, such as muscle cramps, are also documented in regulatory reports.

Q: Why is Kandepres sometimes formulated in a combination pill with a diuretic like hydrochlorothiazide?

Official labeling for these combination products explains the therapeutic rationale. The diuretic component works to reduce fluid volume, which, when combined with Kandepres's action, provides an additive effect that further aids in lowering blood pressure.

Q: What should a patient know if they have a history of liver problems before taking Kandepres?

Official guidelines strictly state that Kandepres is contraindicated (should not be used) in patients with severe hepatic impairment (serious liver problems). For those with moderate liver impairment, official guidelines note that a lower starting dose and careful titration are documented considerations.

Q: Why do official documents often recommend stopping Kandepres before surgery?

Official guidance emphasizes that patients should inform their healthcare provider, including dentists, before any surgical or emergency procedure. This is due to the potential risk of developing excessive low blood pressure (hypotension) during the surgery, which the medication can contribute to.

Q: Can Kandepres affect kidney function, and what monitoring is usually involved?

The medication may cause changes in how the kidneys function. Because of this, official documents detail that periodic monitoring of the blood, checking levels of substances like serum creatinine and potassium, is a documented procedure.

Q: Is Kandepres a cure for high blood pressure, or does it only control the condition?

The medication is officially indicated for the treatment of hypertension (high blood pressure) to lower blood pressure. It is described in regulatory documents as playing a management role to reduce cardiovascular risk, rather than providing a cure.

Q: Does Kandepres help to reduce the risk of stroke or heart attack?

Regulatory information states that lowering blood pressure with this class of drugs is associated with a reduction in the risk of fatal and non-fatal cardiovascular events. This primarily includes the risk of strokes and myocardial infarctions (heart attacks).

Q: Why do some people experience a cough when taking Kandepres, compared to other medications?

Studies have examined the occurrence of cough with this medication. Official documents state that the incidence has been found to be similar to placebo and less likely compared to the related class of ACE inhibitor drugs. Cough is listed as a rare possible side effect.

Q: Does Kandepres cause a feeling of having cold or flu symptoms?

Official documentation lists common adverse reactions that include upper respiratory tract infection, pharyngitis, and rhinitis. These conditions involve inflammation of the throat or nose that may be perceived by a patient as cold or flu-like symptoms.

Q: Do the initial side effects of Kandepres typically go away after the first few weeks?

Official documentation does not contain a general statement on the resolution of all side effects. However, it is noted that certain initial effects, such as those related to additive blood pressure lowering, may be transient (temporary).

Q: Are there any reported long-term side effects associated with years of use?

Official information notes that taking the medication for an extended time can sometimes be associated with a gradual decline in kidney function. This factor contributes to the need for periodic blood monitoring.

Q: Does Kandepres have known interactions with common vitamins or herbal supplements?

Official patient information notes that a healthcare provider should be informed about all vitamins, supplements, and herbs being used. There is a specific warning against products containing potassium, as combining these with the medication can lead to elevated potassium levels in the blood (hyperkalemia).

Q: Can drinking alcohol affect how Kandepres works or increase the risk of side effects?

Official documents state that consuming alcohol may increase the effect of the medication in lowering blood pressure. This could potentially lead to symptoms such as dizziness, lightheadedness, or feeling faint.

Q: Are there common over-the-counter cold or flu medicines that may interact with Kandepres?

Official documentation notes that certain classes of medicines, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), can interact with Kandepres. These drugs, which are often found in over-the-counter cold and flu remedies, may reduce the blood pressure-lowering effect and increase the risk of kidney-related issues.

Q: Are there any known differences in how Kandepres affects people of different ethnic backgrounds?

Research cited in regulatory documents indicates that the blood pressure lowering effect of the medication may be less pronounced in Black patients compared to non-Black patients.

Q: What information is available about using Kandepres in older adults?

Studies have shown that the concentration of the active substance in the blood is higher in older adults compared to younger subjects. However, one specific geriatric analysis found no overall difference in efficacy or safety profiles.

Q: Are there specific research trials that established the role of Kandepres for heart failure?

Official reports and regulatory reviews reference major, large-scale clinical programs that established the role of Kandepres for the treatment of heart failure. One such program is referenced as the CHARM program.

Q: Does the FDA or other agencies have a specific Boxed Warning or major safety warning about Kandepres?

The medication does carry a Boxed Warning (the most serious warning required by the FDA). This warning specifically concerns the risk of fetal toxicity, and the warning notes that the medication should be discontinued as soon as pregnancy is detected.

Q: If Kandepres causes a side effect like fatigue, is there a known reason for this?

Fatigue is listed in official documentation as an adverse effect reported for the class of drugs to which Kandepres belongs. Regulatory documents detail the reported occurrence but do not state a specific physiological reason for its development.

Q: Is it important to take Kandepres at the exact same time every day?

Official documents specify that the drug is taken once daily. The blood pressure-lowering effect generally persists for more than 24 hours, which contributes to its suitability as a once-daily treatment.

Q: What should I know about monitoring blood pressure when starting Kandepres?

Official information indicates that the dose is adjusted according to the patient's blood pressure response. Monitoring is a standard procedure when starting the medication or changing the dose to achieve the desired blood pressure goal.

Q: What are the official guidelines regarding low blood pressure (hypotension) while taking Kandepres?

Official guidelines state that low blood pressure (hypotension) may occur, particularly in patients being treated for heart failure or those with volume depletion. Regulatory documents indicate that patients are typically observed for signs or symptoms of hypotension.

Q: If my blood pressure is under control, can I expect to stop taking Kandepres?

The medication is generally indicated for the long-term treatment of chronic conditions like high blood pressure. Official sources detail the role of consistent use in the long-term management required to maintain blood pressure goals over time.

Q: Are there any dietary restrictions related to salt when taking Kandepres?

Official documentation states that the management of high blood pressure involves comprehensive cardiovascular risk factors. This often includes the appropriateness of limited sodium intake as part of an overall health strategy.

How should Kandepres be stored and disposed of?

How to Store and Dispose of Kandepres

Kandepres (candesartan cilexetil) must be stored strictly according to regulatory labeling to maintain its stability and ensure safe handling.


Required Storage Conditions

Requirement Specific Condition
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C.
Protection Keep the container tightly closed to protect the product from excessive moisture and light.
Container Rule Keep the medication in the original container and out of the sight and reach of children.
Handling Note The extemporaneously prepared suspension must not be frozen and has a shelf-life of 100 days (30 days once opened).

Disposal Instructions

Disposal must adhere to regulatory guidelines to prevent environmental contamination. The preferred method for discarding unused or expired product is through an authorized drug take-back program. If a take-back program is unavailable, disposal must follow the local requirements detailed in the patient information, ensuring that the process prevents the contamination of water supplies.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kandepres found in:

A-Z Index: